Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Geisslinger

Showing results (11-20 of 441) with videos related to

Pageof 45
Sort By:
Pain|August 21, 2007
Current evidence for a modulation of nociception by human genetic polymorphismsJörn Lötsch, Gerd Geisslinger
Trends in Pharmacological Sciences|January 27, 2023
Rethinking the use of NSAIDs in early acute painMarco Sisignano, Gerd Geisslinger
Anesthesiology|January 24, 2008
Proteomics in neuropathic pain researchEllen Niederberger, Gerd Geisslinger
Trends in Molecular Medicine|February 8, 2005
Are mu-opioid receptor polymorphisms important for clinical opioid therapy?Jörn Lötsch, Gerd Geisslinger
Pharmacology & Therapeutics|July 5, 2005
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sitesMaria Burian, Gerd Geisslinger
Expert Review of Proteomics|April 10, 2010
Analysis of NF-kappaB signaling pathways by proteomic approachesEllen Niederberger, Gerd Geisslinger
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 19, 2008
The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?Ellen Niederberger, Gerd Geisslinger
Pharmacology Research & Perspectives|November 27, 2019
Pharmacological plasticity-How do you hit a moving target?Michael J Parnham, Gerd Geisslinger
Biochemical and Biophysical Research Communications|April 7, 2006
Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxibEllen Niederberger, Christine Manderscheid, Gerd Geisslinger
International Journal of Molecular Sciences|September 21, 2017
Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic ReviewKatja Schmitz, Gerd Geisslinger, Irmgard Tegeder
Pageof 45

Showing results (11-20 of 441) with videos related to

Sort By:
Pageof 45
Pain|August 21, 2007
Current evidence for a modulation of nociception by human genetic polymorphismsJörn Lötsch, Gerd Geisslinger
Trends in Pharmacological Sciences|January 27, 2023
Rethinking the use of NSAIDs in early acute painMarco Sisignano, Gerd Geisslinger
Anesthesiology|January 24, 2008
Proteomics in neuropathic pain researchEllen Niederberger, Gerd Geisslinger
Trends in Molecular Medicine|February 8, 2005
Are mu-opioid receptor polymorphisms important for clinical opioid therapy?Jörn Lötsch, Gerd Geisslinger
Pharmacology & Therapeutics|July 5, 2005
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sitesMaria Burian, Gerd Geisslinger
Expert Review of Proteomics|April 10, 2010
Analysis of NF-kappaB signaling pathways by proteomic approachesEllen Niederberger, Gerd Geisslinger
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 19, 2008
The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?Ellen Niederberger, Gerd Geisslinger
Pharmacology Research & Perspectives|November 27, 2019
Pharmacological plasticity-How do you hit a moving target?Michael J Parnham, Gerd Geisslinger
Biochemical and Biophysical Research Communications|April 7, 2006
Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxibEllen Niederberger, Christine Manderscheid, Gerd Geisslinger
International Journal of Molecular Sciences|September 21, 2017
Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic ReviewKatja Schmitz, Gerd Geisslinger, Irmgard Tegeder
Pageof 45